Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing

ArticleAçık Erişim

Özet

Hereditary Breast and Ovarian Cancer (HBOC) syndrome is characterized by an increased risk of developing breast cancer (BC) and ovarian cancer (OC) due to inherited genetic mutations. Understanding the genetic variants associated with HBOC is crucial for identifying individuals at high risk and implementing appropriate preventive measures. The study included 630 Turkish OC patients with confirmed diagnostic criteria of The National Comprehensive Cancer Network (NCCN) concerning HBOC. Genomic DNA was extracted from peripheral blood samples, and targeted Next-generation sequencing (NGS) was performed. Bioinformatics analysis and variant interpretation were conducted to identify pathogenic variants (PVs). Our analysis revealed a spectrum of germline pathogenic variants associated with HBOC in Turkish OC patients. Notably, several pathogenic variants in BRCA1, BRCA2, and other DNA repair genes were identified. Specifically, we observed germline PVs in 130 individuals, accounting for 20.63% of the total cohort. 76 distinct PVs in genes, BRCA1 (40 PVs), BRCA2 (29 PVs), ATM (1 PV), CHEK2 (2 PVs), ERCC2 (1 PV), MUTYH (1 PV), RAD51C (1 PV), and TP53 (1PV) and also, two different PVs (i.e., c.135–2 A>G p.? in BRCA1 and c.6466_6469delTCTC in BRCA2) were detected in a 34-year-old OC patient. In conclusion, our study contributes to a better understanding of the genetic variants underlying HBOC in Turkish OC patients. These findings provide valuable insights into the genetic architecture of HBOC in the Turkish population and shed light on the potential contribution of specific germline PVs to the increased risk of OC. © 2024 Elsevier GmbH

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/11726Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1016/j.prp.2023.155075Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorTuncer, Seref Bugra
dc.contributor.authorCelik, Betul
dc.contributor.authorErciyas, Seda Kilic
dc.contributor.authorErdogan, Ozge Sukruoglu
dc.contributor.authorGültaslar, Busra Kurt
dc.contributor.authorOdemis, Demet Akdeniz
dc.contributor.authorAvsar, Mukaddes
dc.contributor.authorSen, Fatma
dc.contributor.authorSaip, Pınar Mualla
dc.contributor.authorYazici, Hulya
dc.date.accessioned2026-10-18T20:26:43.960368227Z
dc.date.available2026-10-18T20:26:43.960368227Z
dc.date.issued2024
dc.description.abstractHereditary Breast and Ovarian Cancer (HBOC) syndrome is characterized by an increased risk of developing breast cancer (BC) and ovarian cancer (OC) due to inherited genetic mutations. Understanding the genetic variants associated with HBOC is crucial for identifying individuals at high risk and implementing appropriate preventive measures. The study included 630 Turkish OC patients with confirmed diagnostic criteria of The National Comprehensive Cancer Network (NCCN) concerning HBOC. Genomic DNA was extracted from peripheral blood samples, and targeted Next-generation sequencing (NGS) was performed. Bioinformatics analysis and variant interpretation were conducted to identify pathogenic variants (PVs). Our analysis revealed a spectrum of germline pathogenic variants associated with HBOC in Turkish OC patients. Notably, several pathogenic variants in BRCA1, BRCA2, and other DNA repair genes were identified. Specifically, we observed germline PVs in 130 individuals, accounting for 20.63% of the total cohort. 76 distinct PVs in genes, BRCA1 (40 PVs), BRCA2 (29 PVs), ATM (1 PV), CHEK2 (2 PVs), ERCC2 (1 PV), MUTYH (1 PV), RAD51C (1 PV), and TP53 (1PV) and also, two different PVs (i.e., c.135–2 A>G p.? in BRCA1 and c.6466_6469delTCTC in BRCA2) were detected in a 34-year-old OC patient. In conclusion, our study contributes to a better understanding of the genetic variants underlying HBOC in Turkish OC patients. These findings provide valuable insights into the genetic architecture of HBOC in the Turkish population and shed light on the potential contribution of specific germline PVs to the increased risk of OC. © 2024 Elsevier GmbH
dc.description.sponsorshipThe study was approved by the Clinical Research Ethics Committee of Istanbul University (2023/500) and conducted in compliance with the Helsinki Declaration.
dc.identifier.doi10.1016/j.prp.2023.155075
dc.identifier.issn0344-0338
dc.identifier.pmid38219492
dc.identifier.scopus2-s2.0-85182582146
dc.identifier.startpage155075
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/11726
dc.identifier.volume254
dc.language.isoen
dc.publisherElsevier GmbH
dc.relation.ispartofPathology Research and Practice
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBRCA1/BRCA2
dc.subjectGermline Mutations
dc.subjectHBOC
dc.subjectMultigene panels
dc.subjectNGS
dc.subjectOvarian cancer
dc.subjectgenomic DNA
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectbioinformatics
dc.subjectblood sampling
dc.subjectcancer patient
dc.subjectcohort analysis
dc.subjectdisease association
dc.subjectDNA extraction
dc.subjectfemale
dc.subjectgene targeting
dc.subjectgenetic association
dc.subjectgenetic identification
dc.subjectgenetic variability
dc.subjectgermline mutation
dc.subjecthereditary breast cancer
dc.subjecthereditary ovarian cancer
dc.subjecthigh throughput sequencing
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectovary cancer
dc.subjecttumor suppressor gene
dc.subjectTurkey (republic)
dc.titleGermline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus1
rdl.departmentErzincan Binali Yıldırım University, Department of Molecular Biology, Erzincan, Türkiye.
rdl.source.indexSCOPUS
rdl.source.indexPUBMED